E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
First or second degree ankle sprain |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Musculoskeletal Diseases [C05] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the effects of Ibuprofen 5% Topical Gel versus topical placebo for the relief of pain associated with ankle sprain |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the effects of Ibuprofen 5% Topical Gel versus topical placebo for the relief of pain associated with ankle sprain |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- First or second degree ankle sprain within 48 hours of first dose of study medication
- Medically cleared to participate
|
|
E.4 | Principal exclusion criteria |
- Similar injury of same joint within last 6 months
- Requires bed rest, surgery, or over-the-counter or prescription analgesics
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Sum of pain intensity difference on weight bearing over 24 hours after first dose |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
1) Sum of pain intensity difference on weight bearing over 3 days
2) Sum of pain intensity difference at rest over 24 hours
3) Subject Global Assessment of Ankle Injury at Days 3 and 10
4) Ankle Pain at Rest each post-dose time point through 7 days
5) Ankle Pain Upon Weight Bearing Each post-dose time point through 7 days
6) Time weighted sum of pain intensity difference at rest Over 6 hours on Day 1 and over 2 hours on Day 3
7)Time weighted sum of pain intensity difference upon weight bearing Over 6 hours on Day 1 and over 2 hours on Day 3
8) Time weighted pain intensity difference score Over each day, over 3 days, over 7 days
9) Subject assessment of normal function and activity Days 3 and 10
10) Subject Global Assessment of Medication Day 10
11) Time to onset of first perceptible relief First 6 hours after Dose 1
12) Time to onset of meaningful relief First 6 hours after Dose 1
13) Time to rescue medication after initial dose, and after each subsequent dose provided that at least 25% of subjects take rescue medication 10 days
14) Number of doses of rescue medication used First 7 days of dosing
15) Percentage of subjects taking rescue medication 10 days
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1) 3 days
2) 24 hours
3) Days 3 and 10
4) through 7 days
5) through 7 days
6)Over 6 hours on Day 1 and over 2 hours on Day 3
7) Over 6 hours on Day 1 and over 2 hours on Day 3
8) Over each day, over 3 days, over 7 days
9) Days 3 and 10
10) Day 10
11) First 6 hours after Dose 1
12) First 6 hours after Dose 1
13) 10 days
14) First 7 days of dosing
15) 10 days |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 3 |
E.8.9.2 | In all countries concerned by the trial days | 0 |